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Effects of aminoguanidine in preventing experimental diabetic ne-
phropathy are related to the duration of treatment. It has been postulated
that the accumulation of advanced glycation end products (AGEs) in the
kidney is important in the pathogenesis of diabetic ncphropathy. Previ-
ously, aminoguanidine has been shown to inhibit the accumulation of
renal AGEs and to retard the development of experimental diabetic
nephropathy. The present study serially assessed the accumulation of
AGEs in the aorta and kidney, as well as renal functional and structural
parameters over 32 weeks of experimental diabetes in the absence and
presence of aminoguanidine. In addition, it was determined if aminogua-
nidine was more effective if administered earlier or later in the evolution
of diabetic nephropathy by treating diabetic rats with aminoguanidine in
the first or second half of the 32-week study period. In the serial studies,
glomerular and renal tubular fluorescence increased over the 32 week
period and this increase was attenuated by aminoguanidine treatment.
Concomitant with the effects of aminoguanidine on fluorescence, there
was a retardation in the rise in urinary albumin excretion and prevention
of mesangial expansion. Early or late administration of aminoguanidine in
diabetic rats reduced tissue fluorescence in glomeruli and renal tubules. At
32 weeks, renal AGEs were increased in diabetic rats as assessed by tissue
fluorescence. Using a specific RIA, renal AGEs were increased in diabetic
rats and decreased by aminoguanidine treatment, administered over the
entire 32 weeks or in the first or latter half of the 32-week study period.
Aminoguanidine therapy for the entire 32-week study period retarded the
rise in albuminuria in the diabetic rats and was more effective than 16
weeks of treatment either in the first or second half of the study. Early and
late aminoguanidine administration were similar in their capacity to retard
the development of albuminuria in diabetic rats. Similiar effects were
observed on mesangial expansion. The increased glomerular basement
thickness in diabetic rats was not affected by aminoguanidine, irrespective
of duration or timing of therapy. This study confirms that in viva
generation of AGEs in the kidney is time dependent and closely linked to
the development of experimental diabetic nephropathy. The renoprotec-
tive effects of aminoguanidine in diabetes appear to be related to the
duration but not to the timing of treatment.
Advanced glycation end-products (AGEs) accumulate over
time on long-lived proteins including lens crystallin [1] and skin
collagen [2, 3]. It has also been shown that AGEs accumulate in
the circulation of diabetic and non-diabetic patients with renal
failure [41. In many of these studies, AGEs have been quantified
by measurement of the characteristic tissue fluorescence that
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results from a complex reaction in which glucose together with
proteins partake in a process known as the Maillard reaction [2].
It has been postulated that the link between the biochemical
process of advanced glycation and the development of diabetic
complications relates to the presence of AGE products in diabetic
tissues [5] as has been observed in studies in both humans [61 and
rodents [7, 8]. Our group has previously reported increased levels
of AGEs, as defined by tissue fluorescence, in the rat kidney after
32 weeks of streptozocin diabetes [7]. This was associated with
alterations in renal functional as well as structural parameters
such as albuminuria and mesangial expansion. Aminoguanidine, a
hydrazine-like compound (AG), attenuated the rise in albumin-
uria and prevented mesangial expansion in these diabetic rats.
Aminoguanidine treatment also prevented diabetes-related in-
creases in collagen-related fluorescence in the renal glomeruli and
tubules. Ellis and Good have reported in a small number of
animals that AG prevented glomerular basement membrane
thickening [9], but in our previous study no such effect of AG was
observed [7]. Therefore, the effects of AG on the kidney in
experimental diabetes remain controversial.
The hypothesis that the accumulation of AGEs in diabetic
tissues is associated with complications has previously relied on
cross sectional data from diabetic animals [7] and humans [2].
This study has explored the relationship of accumulation of renal
AGEs, measured by radioimmunoassay as well as by tissue
fluorescence, to the development of experimental diabetic ne-
phropathy. In addition, the time course of the effects of ami-
noguanidine in ameliorating diabetes-related renal injury and
inhibiting AGE formation has been assessed. To explore if
aminoguanidine is able to reverse, as well as prevent the develop-
ment of diabetic nephropathy, aminoguanidine was administered
for the whole duration or for the first or second half of the
32-week study period.
Methods
Male Sprague-Dawley rats, six weeks of age, weighing between
200 and 250 g were randomized to control or diabetic groups.
Diabetes was induced by intravenous injection of streptozocin (60
mg/kg body wt in citrate buffer, pH 4.5) afteran overnight fast and
all animals with plasma glucose levels > 20 m after one week
were included in the study. The control group was sham injected
with citrate buffer alone. In the initial study (study protocol I),
diabetic rats were randomized to receive no treatment or ami-
noguanidine (AG) hydrogen carbonate 1 g/liter in drinking water
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(Fluka Chemica, Buchs, Switzerland). Rats were sacrificed at
weeks 0, 8, 16 and 32 weeks. A separate group of control rats
received aminoguanidine (2 glliter in drinking water) and this
group was sacrificed at week 32 only.
Based on the findings of this study that showed a marked
increase in fluorescence and albuminuria in diabetic rats over
weeks 16 to 32 (see below), a second study was performed. In the
latter study (study protocol II), diabetic animals were randomized
into four groups. One group received no therapy, one group
received AG I g/liter in drinking water for the whole 32 week
period, another group was administered AG for the first 16 weeks
of the study only (early intervention), and the final group received
AG for only the last 16 weeks (late intervention). Control rats
received citrate buffer alone.
All rats were given free access to food throughout the study
(GR2 rat cubes; Clark King and Co., Melbourne, Australia).
Diabetic rats received 2 units of ultralente insulin (Ultratard HM;
Novo Industries, Bagsvaerd, Denmark) every second day to
maintain body weight and improve survival over the 32-week study
period. Rats were caged in groups of three. At eight weekly
intervals, rats were weighed and placed in metabolic cages (Iffa
Credo, L'Abresele, France) for collection of 24-hour urine sam-
ples that were stored at —20°C and later assayed for albumin
concentration. Blood was collected from the tail vein at eight
weekly intervals for the measurement of plasma glucose and
glycosylated hemoglobin. Plasma glucose was measured by a
glucose oxidase technique [10] and glycosylated hemoglobin was
measured by a high performance liquid chromatography tech-
nique (Bio-rad, Richmond, CA, USA). Urinary albumin concen-
tration was measured by radioimmunoassay [11]. The interassay
coefficient of variation was 7% (N = 50) at a concentration of 180
ng/ml and the detection limit of the assay was 31.2 ng/ml.
In a subgroup of animals, blood pressure was measured by rat
tail plethysmography [121 and glomerular filtration rate (GFR)
was measured by a single injection isotope technique [131 at 32
weeks.
Rats were anesthetized with pentobarbital sodium (Nembutal,
Bomac, Asquith, Australia) and the left kidney was excised
followed by the removal of the lower abdominal aorta and right
and left common iliac arteries. These tissues were immediately
snap frozen in liquid N2 and stored at —80°C. The preparation of
tissues for measurement of collagen-related fluorescence is out-
lined below and is based on previously published methods [71. In
brief, the left kidney was finely minced and was processed to
isolate glomeruli and tubules. Glomeruli and tubules were sepa-
rated by differential sieving with stainless steel mesh with pore
sizes of 250 to 75 jm yielding 15 to 20,000 glomeruli/kidney. The
purity of the glomerular preparations was greater than 95%. The
aorta was homogenised by a Polytron homgenizer (Ultra-Tumax,
Janke and Kunel, Staufen, Germany). The isolated renal glomer-
uli and tubules as well as the homogenized aorta were suspended
in phosphate buffered saline (pH 7.4) followed by centrifugation
at 15,000 rpm for 30 minutes at 4°C. Lipid extraction of the pellet
was performed by addition of 5 ml of chloroform/methanol (2:1
vol/vol) followed by gentle shaking and standing overnight at 4°C.
The upper layer was removed and the pellet was washed three
times each with methanol and distilled water. The pellet was then
resuspended in 0.5 M acetic acid and I mg/mI pepsin, incubated
for 18 hours at 4°C to remove non-collagenous proteins, and
washed twice with 0.1 M calcium chloride, 0.02 M Tris-HCI (pH
7.5) and 0.05% toluene. No specific fluorescence could be de-
tected in the supernatants at this stage of the extraction proce-
dure. The pellet was then digested with type IV collagenase 0.1
mg/mi, (Sigma, St. Louis, MO, USA) and proteinase K, 0.1 mg/mI,
(Sigma) by gentle shaking at 37°C for 72 hours and centrifuged at
15,000 rpm for 30 minutes at 4°C. The resulting supernatant was
used to measure collagen-related fluorescence with excitation/
emission at 370/440 nm. The fluorescence of an enzyme blank
(type IV collagenase and proteinase K) was subtracted from the
tissue fluorescence measurements. A colorimetric technique was
used for the measurement of protein content [14] of the super-
natants from each of the various tissue sampies. Pilot studies [15]
by our group have indicated that collagen-related fluorescence is
unaffected in control rats receiving aminoguanidine.
A specific radioimmunoassay was developed in our laboratory
for the measurement of advanced glycated end products. The
antibody used in this assay was directed against advanced glycated
RNase [161. AGE-RNase was iodinated using lactoperoxidase
[17]. The AGE-RNase standards (generated as a result of 6
months incubation of RNase with 0.5 M glucose in 0.2 M phosphate
buffer at 37°C) or collagenase extracted renal homogenates,
prepared as described above, were incubated with AGE-RNase
antibody and tracer for five hours at room temperature. Sheep
anti-rabbit IgG was then added and incubated overnight at room
temperature. Precipitation of proteins was carried out by addition
of 8% polyethylene glycol. The minimum concentration detect-
able was 250 mg/ml and the CV of this assay was 11.9%, N = 4,
at a concentration of 2000 ng AGE-RNase/ml. Radioactivity was
measured using a gamma counter (Canberra Packard Instru-
ments, St. Louis, MO, USA) and the amount of AGEs present
was expressed as ng AGE-RNase/j.tmol hydroxyproline. Hy-
droxyproline was measured in tissue samples by a colorimetric
technique [18].
The right kidney was perfused in vivo at systolic blood pressure
by an intra-aortic cannula initially with saline, followed by 2.5%
glutaraldehyde [19]. A portion of the fixed kidney was prepared
for electron microscopy. Briefly, 1 mm3 cubes were obtained from
deep areas of the renal cortex at least 4 mm from the external
surface and these sections were left for an additional 12 hours in
the glutaraldehyde fixative followed by 0.1 M phosphate buffer for
72 hours. The blocks were then rehydrated in acetone followed by
infiltration with araldite-Epon resin. The blocks were polymerised
in an oven at 60°C for three days. Thick sections (1 rm) were cut
and placed on a slide and stained with methylene blue. Glomeruli
were located with light microscopy, the blocks trimmed and 50 nm
sections cut. Sections were picked up on a Formvar-coated
single-hole grid (SPI, Westchester, PA, USA) saturated with
uranyl nitrate and Reynold's lead citrate and viewed using a Jeol
1200EX transmission electron microscope (Jeol, Tokyo, Japan).
Twenty evenly spaced electron photomicrographs at a final mag-
nification of approximately X 18,000 were taken with a 5 X 4 grids
from 2 glomeruli per rat. GBM thickness was measured by the
orthogonal intercept method [201. At least 50 orthogonal inter-
cept measurements were performed on each glomerulus. As
previously described [21, 22], mesangium was defined as the areas
delineated towards the capillary basement membrane where the
endothelial and epithelial sides of the basement membrane are
running parallel. Where the parallelism was lost and the distance
between endothelial and epithelial cells widened it was viewed
that this was the site where the mesangial region had ended.
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Group 8 weeks 16 weeks 32 weeks
Number Control
Diabetic
Diabetic+AG
6
6
6
11
6
9
16
25
22
Body weight g Control
Diabetic
Diabetic+AG
396 8
176 4
251 18
460 25
220 17
220 17
626 16
339 18
329 17
Glucose Control 8.2 0.3 4.9 0.8 8.5 0.4
mmollliter Diabetic
Diabetic+AG
4.3 0.4
3.9 1.3
25.3 3.8
29.4 3.8
37.4 3.1
39.1 2.0
HbAlc % Control
Diabetic
Diabetic+AG
1.6 0.2
4.3 0.4
3.9 0.4
1.7 0.4
4.6 0.3
4.6 0.3
2.2 0.2'
4.1 0.3
3.9 0.2
Fractional mesangial volume was determined after mesangium
had been identified in the electron micrographs by an indepen-
dent observer. A point-counting method was used with a 180-
point grid to determine the percentage of glomerular tuft occu-
pied by the mesangium [22]. Two glomeruli were studied per rat
with a mean CV between glomeruli of 14%.
Statistics
Logarithmic transformation of urinaly albumin data were per-
formed to yield a normal distribution for this parameter. The
specific contributions of diabetes, time and aminoguanidine ther-
apy and possible interactions were assessed by analysis of vari-
ance. Only data from animals which survived until time of sacrifice
were analyzed. Up to 30% of diabetic rats died before week 32,
the majority of deaths occuring in the first four weeks. There was
no difference in survival between untreated and aminoguanidine
treated diabetic rats. Comparison of normally distributed vari-
ables among the different groups during the study was performed
by analysis of variance with or without repeated measures using
the Statview SE Program (Brainpower, Calabasas, CA, USA) on
a Macintosh LC475 personal computer (Apple, Cupertino CA,
USA). Comparisons among groups at specific time points were
performed by Fisher's least significant difference method. A P
value of less than 0.05 was viewed as statistically significant. All
data are shown as mean SE unless otherwise specified.
Results
Study protocol I
Serial body wt and glycemic control are shown in Table 1.
Diabetic rats had significantly lower body wts than control rats
throughout the duration of the study. Aminoguanidine therapy
did not influence body wt in diabetic rats over the 32 weeks of
treatment. Diabetes was associated with significantly elevated
glucose and HbAlc levels throughout the study when compared to
control rats. Aminoguanidine therapy did not influence glycemic
control in diabetic rats at any time point. Control rats treated with
aminoguanidine had similar plasma glucose levels (7.8 0.4, N =
11) and HbAlc (2.1 0.2%, N = 11) to untreated control rats. In
the groups studied for 32 weeks, there was no effect of AG on
systolic blood pressure (Control, 121 8; Diabetes, 142 12;
Diabetes+AG, 131 4 mm Hg).
Renal fluorescence (glomeruli and tubules) for the various
groups is shown in Figure 1. In diabetic rats there was an increase
in glomerular and tubular fluorescence over time, leading to
significantly increased levels at 8, 16, and 32 weeks in diabetic
compared to control rats. Aminoguanidine attenuated the rise in
glomerular as well as tubular fluorescence in the diabetic rats so
Table 1. Study protocol I: Serial glycemic control and weight A
4
3
*
Results are means SE.
aP < 0.01 vs. Diabetic, Diabetic+AG
2 t
*
*
0
0 8 16 32
Time, weeks
B
*
4
. 3
ci>
c:.
i
0
8
Time, weeks
Fig. 1. Fluorescence corrected for protein content (arbitrary units/mg pro-
tein) are shown for study protocol I in (A) glomerul4 (B) Renal tubules at 0,
8, 16 and 32 weeks. Results are means SE in Control (LII), Diabetic (U),
and Diabetic + aminoguanidine (hI). *P < 0.01 versus Control, tP < 0.01
versus Diabetic.
*
*
t
0 16 32
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Table 2. Study protocol I: Serial functional and structural data
Group 8 weeks 16 weeks 32 weeks
Albuminuria mg/24 hr Control
Diabetic
Diabetic+AG
0.5 x!÷ 0.07
2.2 X/+ OP
2.4 X/+ 0.13a
0.6 x/-- 0.12
2.5 X/+ O.13'
2.0 ></. 012ah
1.0 x/÷ 0.16
15.9 x/-- 0.10
2.0 x/-- 0.10"
Fractional mesangial volume % Control
Diabetic
Diabetic+AG
10.2 1.7
17.0 3.1"
12.9 1.4"
12.8 1.0
14.2 0.7
12.9 0.7
14.5 0.9
16.3 0.7'
13.0 07h
GBM thickness nm Control
Diabetic
Diabetic+AG
122.8 2.6
130.2 1.8
112.4 1.6"
142.5 3.2
146.1 3.8
147.2 7.7
163.4 2.6
186.9 7.7"
189.1 3.5'
Results are means SE except for albuminuria which is shown as geometric mean x/± tolerance factor.
a P < 0.05 vs. Control
h P < 0.05 vs. Diabetic
Table 3. Study protocol II: Glycemic control and weight
Control Diabetic
Diabetic+aminoguanidine weeks
0—32 0—16 16—32
Number 12 12 9 6 15
Body weight g
0 weeks 267 8 271 18 245 13 267 25 225 30
16 weeks 545 19' 342 36 385 26 268 26" 322 31
32 weeks 715 27' 403 34 442 28 294 14" 327 27"
Glucose
8—32 weeks 7.8 0.1' 31.0 2.4 31.0 1.8 30.5 1.7 30.5 0.8
mean!
mmol/liter
HbAlc
8—32 weeks 2.1 4.5 0.2 4.0 0.3 4.3 0.2 4.3 0.2
mean/%
Results are means SE.
ap < 0.01 vs. all groups.
"P < 0.01 vs. Diabetic and Diabetic+aminoguanidine (0—32 weeks)
that tissue fluorescence approximated levels observed in control
rats at 8, 16 and 32 weeks.
Serial functional and structural data are shown in Table 2.
Albuminuria levels increased in control and diabetic rats over the
study period. Diabetes was associated with significantly increased
albuminuria over the 32-week study period when compared to
control rats. Treatment of diabetic rats with aminoguanidine
significantly retarded the rise in albuminuria at 16 and 32 weeks.
In control rats treated with aminoguanidine, there was no effect
on albuminuria (week 32, control + aminoguanidine, 1.0 X/± 0.1
mg/24hr,N= 11).
Fractional mesangial volume was not increased in control rats
over time. However, there was a significant increase in mesangial
expansion in diabetic compared to control rats at weeks 8 and 32.
There was a trend towards an increase at week 16 but this did not
reach statistical significance (P < 0.10). The increase in mesangial
expansion was significantly attenuated by aminoguanidine therapy
at weeks 8 and 32. No effect of aminoguanidine on this parameter
was observed in control rats (week 32, 13.6 0.8%). GBM
thickness increased over the 32 weeks study period in both control
and diabetic rats. Diabetes was associated with a significant
increase in GBM thickness at week 32. Aminoguanidine therapy
did not reduce glomerular basement membrane thickness in
diabetic rats at week 32. No effect of aminoguanidine was observed
on GBM thickness in control rats at week 32 (168 5 nm).
Study protocol II
Glycemic controls and body weights are shown in Table 3.
There was a significant increase in body weight over time in
both control and diabetic rats. Administration of aminoguanidine
throughout the study period, did not affect body weight. Early as
well as late intervention with aminoguanidine in diabetic rats was
associated with a slight decrease in body weight at 32 weeks when
compared to untreated animals. However, this retarded weight
gain was not reflected by differences in glycemic control. Diabetes
was associated with a significant elevation in plasma glucose levels
as well as glycosylated hemoglobin. Aminoguanidine therapy
whether it was administered throughout, early or late in the
experimental procedure did not influence plasma glucose or
HbAlc.
There was a significant increase in aortic fluorescence corrected
for protein content in diabetic rats (control 1.58 0.49, diabetic
3.68 0.22, arbitrary units/mg protein, P < 0.01). Chronic
therapy with aminoguanidine prevented the increase in aortic
fluorescence resulting in levels from diabetic rats being similar to
those observed in control rats (diabetic + aminoguanidine 2.29
0.19, arbitrary units/mg protein, P < 0.01 vs. diabetic). Early (0 to
16 weeks) as well as late (16 to 32 weeks) administration of
aminoguanidine prevented the increase in aortic fluorescence to a
similar degree (early intervention 1.64 0.42; late intervention
1.07 0.31, arbitrary units/mg protein, P < 0.01 vs. diabetic).
In isolated renal tubules and glomeruli, diabetes was associated
with a significant increase in fluorescence and this was prevented
by administration of aminoguanidine to a similar degree whether
it was given throughout, early or late in the experimental protocol
(Fig. 2).
The amounts of advanced glycation end products, as assessed
by RIA, in renal glomeruli and tubules at 32 weeks are shown in
Figure 3. There was a significant increase in AGEs in homoge-
nates from glomeruli and tubules of the diabetic rats when
compared to control rats at week 32. Treatment with aminogua-
nidine, administered either throughout the 32 weeks period or for
the first or latter 16 weeks of the entire study period, reduced
AGEs levels in renal homogenates at week 32.
There was a significant increase in albuminuria over the 32
week study in diabetic rats as compared to control rats (Fig. 4).
The rise in albuminuria in diabetic rats was markedly attenuated
by aminoguanidine therapy with levels in this group being lower
than in the untreated diabetic rats at 8, 24 and 32 weeks,
*oa
Control Diabetic Diabetic + aminoguanidine
0—32 0—16 16—32
B weeks weeks weeks
* * **
T
Control Diabetic Diabetic + aminoguanidine
0—32 0—16 16—32
weeks weeks weeks
A4
3
2
1
*
3
2
1
0
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Fig. 2. Fluorescence corrected for protein content (arbitraiy units/mg pro-
tein) are shown for study protocol Ii in (A) glomeruli and (B) renal tubules
at 32 weeks. Results are means SE in Control, Diabetic and Diabetic +
aminoguanidine either for the duration of the study (0 to 32 weeks), early
intervention (0 to 16 weeks), or late intervention (16 to 32 weeks).
0.01 versus Diabetic.
respectively. At week 16 there was a trend towards less albumin-
uria in AG treated rats but this did not reach statistical signifi-
cance. Urinary albumin excretion in the early and late interven-
tion groups at 24 and 32 weeks was intermediate between the
results of rats treated with AG throughout and untreated diabetic
rats. At week 16, the early but not the late intervention group had
lower levels of albuminuria than the untreated diabetic rats.
Diabetic rats had significantly increased fractional mesangial
volume at 32 weeks as compared to control rats. Chronic admin-
istration of aminoguanidine significantly inhibited mesangial ex-
pansion at 32 weeks as compared to control rats. The effects of
early or late intervention with aminoguanidine on mesangial
expansion were intermediate between untreated diabetic rats and
chronically aminoguanidine treated rats. Diabetes was associated
with significantly increased GBM thickness at 32 weeks when
compared to control rats. Administration of aminoguanidine
whether it was throughout, early or late did not significantly affect
GBM thickness in diabetic rats at 32 weeks.
Discussion
In the present study we have confirmed that in vivo generation
of AGEs, as measured by tissue fluorescence, is time dependent.
Fig. 3. Advanced glycation end product levels, as measured by RIA, are
shown for study protocol II in glomeruli (A) and renal tubules (B) at 32
weeks. Results are means SE in Control, Diabetic and Diabetic +
Aminoguanidine either for the duration of the study (0 to 32 weeks), early
intervention (0 to 16 weeks), or late intervention (16 to 32 weeks). *p <
0.01 versus Diabetic.
Similar findings of increased AGEs in diabetes have been previ-
ously described using various techniques including tissue fluores-
cence [7, 8, 23, 24], immunochemical methods [4, 6, 16] and
radioreceptor assays [25]. Concomitant with the increase in tissue
advanced glycation end products there was evidence of diabetic
nephropathy, as assessed by both structural and functional param-
eters.
Administration of aminoguanidine throughout the entire study
period prevented accumulation of kidney AGEs. In addition, we
have confirmed our previous finding that aminoguanidine ame-
liorates the development of diabetic nephropathy, as defined by
attenuation of the rise in albuminuria and prevention of mesan-
gial expansion [7]. As in our previous study, the increase in GBM
thickening in diabetic rats was not influenced by aminoguanidine
treatment. Others have recently shown that aminoguanidine
ameliorates experimental diabetic nephropathy. In long-term
diabetic Wistar rats, aminoguanidine attenuated both urinary
A
200000
150000
100000 *I
50000 1 *
0
Control Diabetic Diabetic + aminoguanidine
0—32 0—16 16—32
weeks weeks weeks
B
250000
200000
150000
100000
50000
0
Control Diabetic Diabetic + aminoguanidine
0—32 0—16 16—32
weeks weeks weeks
632 Soulis et a!: Aminoguanidine and diabetic nephropathy
40
30
20
E
10
0
Time, weeks
Fig. 4. Serial data for albuminuria (y-axis, logarithmic scale) are shown for
study protocol II at eight weekly intervals are shown for Control (LII), Diabetic
•), Diabetic + aminoguanidine either for the duration of the study chronic
(0 to 32 weeks, •), early intervention (0 to 16 weeks, A), or late intervention(16 to 32 weeks, A). Results are shown as geometric means and tolerance
factors. Week 8: P < 0.05 diabetic + chronic AG versus diabetic + late
intervention; P < 0.05 diabetic + late intervention versus diabetic + early
intervention, P < 0.01 diabetic versus control, diabetic + late intervention.
Week 16: P < 0.01 diabetic vs. control, P < 0.05 diabetic + late
intervention vs. control; P < 0.01 diabetic vs. diabetic + early intervention.
Week 24: P < 0.01 all diabetic groups vs. control, P < 0.01 diabetic +
chronic AG vs. diabetic. Week 32: P < 0.01 diabetic vs. control, diabetic
+ early intervention vs. control, diabetic + late intervention vs. control,
P < 0.01 diabetic + chronic AG vs. diabetic, P < 0.05 diabetic + chronic
AG vs. diabetic + early intervention, diabetic + chronic AG vs. diabetic
+ late intervention.
albumin and high molecular weight protein excretion [26]. In rats
with diabetes and genetic hypertension, aminoguanidine retarded
the development of albuminuria over a 16 weeks study period
[27]. We have previously shown that AG therapy does not
significantly influence albuminuria or tissue fluorescence in con-
trol rats after 16 weeks of therapy [15]. In the present study, in
another group of control rats treated with AG for 32 weeks, a
similar lack of effect of AG on albuminuria or on any renal
strucural parameter was noted. Other groups have also shown no
effect of AG on albuminuria [26] or on kidney related fluores-
cence [8] in non-diabetic rats. These findings are consistent with
AG having a specific role in states of chronic hyperglycemia.
One cannot exclude that AG could exert its beneficial effects via
other mechanisms including reduction in blood pressure or pre-
venting hyperfiltration. However, in the present study, AG did not
influence blood pressure or GFR (data not shown). It should be
appreciated that the model of STZ diabetes in the Sprague-
Dawley rat is not associated with renal impairment [28]. There-
fore, one cannot predict from these studies if agents such as AG
could prevent the decline in renal function in humans.
Aminoguanidine has also been shown to favorably influence
retinopathy [29] and neuropathy [30] in experimental diabetes. A
recent study by Huijberts et al has reported that aminoguanidine
Table 4. Study protocol II: Structure at 32 weeks
Mesangium % GBM nm
Control 11.9 1.P 157.1 s.r'
Diabetic 18.0 1.1 197.9 4.7
Diabetic+AG 12.1 1.0 185.6 5.2
Diabetic+early AG 14.5 1.2 205.2 8.1
Diabetic+late AG 15.9 2.0 212.0 6.6
Results are means SE.
"P < 0.01 vs. Diabetic
can reduce regional albumin clearances across various tissue beds
although the kidney was not specifically studied [31]. No effect on
urinary albumin excretion was observed in that study which was
only eight weeks in duration.
To explore the specificity of the changes in tissue fluorescence
a recently developed radioimmunoassay was used to measure
advanced glycation end products. This assay confirmed that
diabetes is associated with an increase in AGEs in both glomeruli
and renal tubules and that these changes could be prevented by
aminoguanidine therapy (Fig. 3). Using immunohistochemical
techniques we have also demonstrated the presence of AGEs in
both glomeruli and renal tubules [32]. RAGE (receptor to
advanced glycation end products), a 30 kDa protein postulated to
be involved in AGE actions, has been reported to be present in
the kidney [33]. In studies which included use of an antibody to
human RAGE, advanced glycated products and RAGE appeared
to co-localize in glomeruli and distal tubules [32].
Even though the effect of aminoguanidine in retarding renal
injury has been confirmed in the present study, its mechanism of
action remains unclear. The ability of aminoguanidine to reduce
tissue fluorescence suggests that its major action is via prevention
of AGE product accumulation. However, fluorescence per se
cannot be considered specific for AGEs since other compounds
such as oxidation products may fluoresce [34]. This is further
complicated by a well described interaction between glycation and
oxidation resulting in glycoxidation products, some of which
fluoresce [35]. A recent study by Dyer et al has shown a strong
correlation between glycoxidation products such as carboxymeth-
yllysine and pentosidine and tissue fluorescence in both control
and diabetic patients [2]. Our group has compared treatment of
diabetic rats with either antioxidants or aldose reductase inhibi-
tors with aminoguanidine treatment [36]. These agents failed to
reproduce the renal effects of aminoguanidine over 32 weeks. This
suggests that the in vivo effects of aminoguanidine are mediated
predominantly via inhibition of advanced glycation rather than by
inhibition of alternative pathways such as the polyoi pathway or
oxidation alone. In the present study, the ability of AG to reduce
renal AGEs, as assessed by radioimmunoassay, provides further
evidence that AG acts predominantly as an inhibitor of advanced
glycation.
The major structural parameter to be ameliorated by ami-
noguanidine was mesangial expansion which has been postulated
to be a central mechanism in the progression of diabetic renal
injury [37]. Recently, Anderson et al have shown that in vitro
glycation of extracellular matrix could influence mesangial cell
behavior [38]. However, this group did not differentiate between
early and advanced glycation. This is of particular significance
because of recent studies suggesting that Amadori products may
participate in the genesis of renal injury in diabetes [39, 40]. In the
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present study, there was a tendency for mesangial exxpansion to
already be apparent after only a short period of diabetes. This is
consistent with previous studies which have observed that in-
creases in mesangial volume are already detectable after 8 or 24
weeks of diabetes [41, 421. Furthermore, islet transplantation has
been shown to reverse mesangial expansion in diabetic rats within
eight weeks [43], consistent with the ability of glucose-dependent
mechanisms to rapidly influence this glomerular ultrastructural
parameter [43].
The link between AGEs and mesangial expansion is further
strengthened by several reports indicating that receptors for
advanced glycation products are present in mesangial cells [33,
44]. It appears likely that mesangial expansion in diabetes not only
involves increased synthesis of matrix components but also a
decrease in matrix degradation [45]. Aminoguanidine has been
shown to normalize the defect in matrix degradation that occurs
when matrix is incubated in a high glucose medium [45]. There-
fore it is possible that the effects of aminoguanidine in preventing
mesangial expansion, may be in part due to the capacity of this
drug to normalize mesangial matrix degradative processes.
A recent study has shown that AGE-modified mouse serum
albumin injected intraperitoneally for four weeks was associated
with an increase in the messenger RNA for various extracellular
matrix components and growth factors including alpha-i IV
collagen, laminin Bi and transforming growth factor -1 [461. In
addition, aminoguanidine was able to inhibit these increases in
growth factor and matrix component gene expression. These
findings would be consistent with aminoguanidine preventing
mesangial expansion by inhibiting AGE-dependent mechanisms
which regulate growth factor and extracellular matrix synthesis.
More recently, this group has demonstrated that administration of
in vitro prepared AGEs to normal rats for five months leads to
advanced pathological changes in renal glomerular structure and
function [47]. These rats developed albuminuria and an increase
in mesangial matrix. These changes were associated with in-
creased renal and serum AGE levels. Aminoguanidine was able to
inhibit the accumulation of renal AGEs as well as preventing
albuminuria in this model. However, it is not known how closely
the pathology of the renal lesion in response to administration of
in vitro generated AGEs reflects diabetic nephropathy in other
respects.
Treatment with aminoguanidine for 32 weeks was more effec-
tive in preventing renal injury than 16 weeks of treatment, either
early or late. These findings are consistent with a recent study that
showed that the duration of AG treatment was important in
retarding the progression of experimental retinopathy [48].
There was no difference between early and late intervention
with respect to albuminuria or mesangial expansion. This would
indicate that aminoguanidine treatment has a role not only in
preventing diabetic complications but that this agent could also be
considered in the setting of established diabetic renal disease.
Interestingly, our study showed no difference in the effect of
aminoguanidine on tissue fluorescence when the drug was given
throughout the study, or when it was administered early or late
(Fig. 2). By contrast, the effects of aminoguanidine on albumin-
uria and renal structure, as described above, were influenced by
duration of therapy. Possible explanations for this difference may
be that not all AGEs are fluorescent [49] or that the tissue
fluorescence observed in this study reflects other processes as well
as advanced glycation. Therefore a direct link between tissue
fluorescence and renal structural changes in diabetes remains to
be determined. The link between tissue levels AGE and albumin-
uria has been recently studied in diabetic patients by Beisswenger
et al [50]. In that study advanced glycation end products, as
assessed by collagen-linked fluorescence and pentosidine, mea-
sured by a specific HPLC technique, were found to correlate with
micro- and macroalbuminuria.
The present results are consistent with the hypothesis that
advanced glycation is an important pathogenetic process in the
development of diabetic complications, including nephropathy.
The demonstration that aminoguanidine therapy has a renopro-
tective effect and that the effect is related to the duration of
therapy, emphasises its potential importance in the clinical situa-
tion. Although caution is needed in extrapolating the results of
experimental studies to clinical diabetes, the potent effects of
aminoguanidine on diabetic microvascular complications ob-
served in experimental studies should be a major impetus to
further explore the effects of this drug in humans.
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